Key Takeaways Eli Lilly's Zepbound can be covered by Medicare Part D plans after the FDA approved the drug as a treatment for ...

Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 494.50% and ...

Investors seeking the next obesity-like market opportunity will be closely watching developments related to treatments for ...

Alzheimer’s drugs could unlock a $13 billion market by 2030, with Biogen, Eli Lilly, Novo Nordisk, Roche, and UCB leading the ...

Investors seeking the next obesity-like market opportunity will be closely watching developments related to treatments for ...

Startup Virta Health saw 60% revenue growth last year, topping $100 million, driven by demand for its employer weight loss ...

Nina Kritzberger, 16, speaks before the Government and Veteran Affairs Committee in favor of an insulin cap for the North ...

Medicare has announced the expansion of coverage for Eli Lilly’s Zepbound, a breakthrough drug in the treatment of autoimmune ...

Deutsche Bank analyst Emmanuel Papadakis lowered the firm’s price target on Novo Nordisk (NVO) to DKK 900 from DKK 1,000 and keeps a Buy rating ...

Eli Lilly in talks to acquire cancer biotech Scorpion Therapeutics for $2.5 billion, with potential milestone payments.